Approaches to dyslipidemia treatment in children and adolescents

Expert Review of Endocrinology and Metabolism

Volumn 3, Issue 5, 2008, Pages 615-633

  Iughetti, Lorenzo ^a   Predieri, Barbara ^a   Bruzzi, Patrizia ^a   Balli, Fiorella ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Bile acid binding resin; Children; Diet; Dyslipidemia; Familial hypercholesterolemia; HMG CoA reductase inhibitor; Low density lipoprotein

Indexed keywords

ATORVASTATIN; AVASIMIBE; BILE ACID SEQUESTRANT; COLESTILAN; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MANNAN; MEVINOLIN; NICOTINIC ACID; PHYTOSTEROL; PLACEBO; PRAVASTATIN; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; ROSUVASTATIN; SATURATED FATTY ACID; SERINE PROTEINASE; SIMVASTATIN; UNCLASSIFIED DRUG; VITAMIN;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ABSENCE OF SIDE EFFECTS; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANGINA PECTORIS; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY GROWTH; BODY HEIGHT; BODY MASS; BODY WEIGHT; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CHILD; CHILD NUTRITION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CORTICOTROPIN BLOOD LEVEL; CREATINE KINASE BLOOD LEVEL; DIET THERAPY; DIETARY FIBER; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG GRANULE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ESTRADIOL BLOOD LEVEL; EXERCISE; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; FAT INTAKE; FATIGUE; FITNESS; FLATULENCE; FLU LIKE SYNDROME; FOLIC ACID BLOOD LEVEL; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENETIC SCREENING; GONAD; GONAD VOLUME; GROWTH DISORDER; HEARTBURN; HETEROZYGOSITY; HOMOCYSTEINE BLOOD LEVEL; HOMOZYGOSITY; HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; INSOMNIA; JAUNDICE; LIFESTYLE MODIFICATION; LIVER TOXICITY; LOOSE FECES; LOW DRUG DOSE; LYMPHADENOPATHY; MENSTRUAL CYCLE; MISSENSE MUTATION; MONOTHERAPY; MUSCLE CRAMP; MUSCLE TENDERNESS; MYALGIA; MYOPATHY; NAUSEA; OBESITY; PAIN; PATIENT COMPLIANCE; PEDIATRICS; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SEXUAL DEVELOPMENT; SEXUAL MATURATION; SIDE EFFECT; SLEEP DISORDER; STOMACH PAIN; TESTIS SIZE; TESTOSTERONE BLOOD LEVEL; THORAX PAIN; THYROTROPIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN BLOOD LEVEL; VOMITING; WEIGHT GAIN;

EID: 55649083293     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/17446651.3.5.615     Document Type: Review

References (124)

1. Berenson GS, Srinivasan SR, Bao W, Newman WP, Tracy RE, Wattingney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: the Bogalusa Heart Study. N. Engl. J. Med. 338, 1650-1656 (1998).
2. Srinivasan SR, Frontini MG, Xu J, Berenson GS. Utility of childhood non-high-density lipoprotein cholesterol levels in predicting adult dyslipidemia and other cardiovascular risks: the Bogalusa Heart Study. Pediatrics 118(1), 201-202 (2006).
3. Iughetti L, Volta C, Maggi E et al. Circulating antibodies recognizing oxidatively modified low-density lipoprotein in children. Pediatr. Res. 45, 94-99 (1999).
4. Rodenburg J, Visser MN, Wiegman A et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J. Am. Coll. Cardiol. 47, 1803-1810 (2006).
5. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: The Metabolic and Molecular Bases of Inherited Disease (8th Edition). Scriver CR, Beaudet AL, Sly WS et al (Eds). McGraw-Hill, NY, USA 2863-2913 (2001).
6. Wiegman A, Rodenburg J, de Jongh S et al. Family history and cardiovascular risk in familial hypercholesterolemia: data in more than 1000 children. Circulation 107, 1473-1478 (2003).
7. Gidding SS. Dyslipidemia in the metabolic syndrome in children. J. Cardiomet. Syndr. 1(4), 282-285 (2006).
8. Daniels SR, Greer FR; The Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics 122, 198-208 (2008).
9. Civiera F. International panel on management of familial hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 173, 55-68 (2004).
10. Tosi I, Toledo-Leiva P, Neuwirth C et al. Genetic causes of familial hypercholesterolemia: identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic. Atherosclerosis 194(1), 102-111 (2007).
11. Burnett JR, Hooper AJ. Common and rare gene variants affecting plasma LDL cholesterol. Clin. Biochem. Rev. 29, 11-26 (2008).
12. Rouis M, Dugi KA, Previato L et al. Therapeutic response to medium-chain triglycerides and omega-3 fatty acids in a patient with the familial chylomicronemia syndrome. Arterioscler. Thromb. Vasc. Biol. 17, 1400-1406 (1997).
13. Miller M. Current perspectives on the management of hypertriglyceridemia. Am. Heart J. 140, 232-240 (2000).
14. Vobecky JS, David P, Vobecky J. Dietary habits in relation to tracking of cholesterol level in young adolescents: a nine-year follow-up. Ann. Nutr. Metab. 32, 312-323 (1998).
15. Porkka KV, Viikari JS, Akerblom HK. Tracking of serum HDL-cholesterol and other lipids in children and adolescents: the Cardiovascular Risk in Young Finns Study. Prev. Med. 20, 713-724 (1991).
16. Webber LS, Srinivasan SR, Wattigney WA, Berenson GS. Tracking of serum lipids and lipoproteins from childhood to adulthood. The Bogalusa Heart Study. Am. J. Epidemiol. 133, 884-899 (1991).
17. Leren TP. Cascade genetic screening for familial hypercholesterolemia. Clin. Genet. 66, 483-487 (2004).
18. Dennison BA, Kikuchi DA, Srinivasan SR, Webber LS, Berenson GS. Serum total cholesterol screening for the detection of elevated low-density lipoprotein in children and adolescents: the Bogalusa Heart Study. Pediatrics 85, 472-479 (1990).
19. Wald DS, Bestwick JP, Wald NJ. Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. BMJ 335, 599-566 (2007).
20. Nicholls DP, Cather M, Byrne C, Graham CA, Young IS. Diagnosis of heterozygous familial hypercholesterolemia in children. Int. J. Clin. Pract. 62, 990-994 (2008).
21. McCrindle BW, Urbina EM, Dennison BA et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in Young, with the Council on Cardiovascular Nursing. Circulation 115, 1948-1967 (2007).
22. US Preventive Service Task Force. Screening for lipid disorders in children: US Preventive Service Task Force recommendation statement. Pediatrics 120, e215-e219 (2007).
23. Parente EB, Guazzelli I, Riberio MM et al. Obese children lipid profile: effects of hypocaloric diet and aerobic physical exercise. Arg. Bros. Endocrinol. Metab. 50(3), 499-504 (2006).
24. American Heart Association. Diagnosis and treatment of primary hyperlipidemia in childhood: a joint statement for physicians by the committee on atherosclerosis and hypertension in childhood on the council of cardiovascular disease in the young and the nutrition committee. Circulation 74, 1181-1187 (1986).
25. Shamir R, Fisher EA. Dietary therapy for children with hypercholesterolemia. Am. Fam. Phys. 61, 675-686 (2000).
26. Williams CL, Haymen LL, Daniels SR et al. Cardiovascular health in childhood. A statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on cardiovascular disease in the young, American Hearth Association. Circulation 106, 143-160 (2002).
27. American Academy of Pediatrics. National Cholesterol Education Program: report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 89, 525-584 (1992).
28. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143-3421 (2002).
29. Hansen D, Michaelsen KF, Skovby F. Growth during treatment of familial hypercholesterolemia. Acta Paediatr. 81, 1023-1025 (1992).
30. Kaplan RM, Toshima MT. Does a reduced fat diet cause retardation in child growth? Prev. Med. 21, 33-52 (1992).
31. Lifshitz F, Tarim O. Considerations about dietary fat restrictions for children. J. Nutr. 126, 1031S-141S (1996).
32. DISC Collaborative Research Group. Dietary Intervention Study in Children (DISC) with elevated low-density-lipoprotein cholesterol: design and baseline characteristics. Ann. Epidemiol. 3, 393-403 (1993).
33. The Writing Group for the DISC Collaborative Research Group. Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol: the Dietary Intervention Study in Children (DISC). JAMA 273, 1429-1435 (1995).
34. Lauer RM, Obarzanek E, Hunsberger SA et al. Efficacy and safety of lowering dietary intake of total fat, saturated fat, and cholesterol in children with elevated LDL cholesterol: the Dietary Intervention Study in Children. Am. J. Clin. Nutr. 72, 1332S-1342S (2000).
35. Obarzanek E, Kimm SYS, Barton BA et al. Long-term safety and efficacy of a cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary Intervention Study in Children. Pediatrics 107, 256-264 (2001).
36. Lapinleimu H, Viikari J, Jokinen E et al. Prospective randomized trial in 1062 infants of diet low in saturated fat and cholesterol. Lancet 345, 471-476 (1995).
37. Simell O, Niinikoski H, Rönnemaa T et al. Special Turku Coronary Risk Factor Intervention Project of babies (STRIP). Am. J. Clin. Nutr. 72, 1316S-1331S (2000).
38. Rask-Nissilä L, Jokinen E, Rönnemaa T et al. Prospective, randomized, infancy-onset trial of the effects of a low-saturated-fat, low-cholesterol diet on serum lipids and lipoprotein before school age. The Special Turku Coronary Risk Factor Intervention Project (STRIP). Circulation 102, 1477-1483 (2000).
39. Kaitosaari T, Rönnemaa T, Raitakari O et al. Effect of 7-year infancy-onset dietary intervention on serum lipoproteins and lipoprotein subclasses in healthy children in the prospective, randomized Special Turku Coronary Risk Factor Intervention Project for children (STRIP) study. Circulation 108, 672-677 (2003).
40. Lagström H, Seppänen R, Jokinen E et al. Influence of dietary fat on the nutrient intake and growth of children from 1 to 5 years of age: the Special Turku coronary Risk factor Intervention Project. Am. J. Clin. Nutr. 69, 516-523 (1999).
41. Rask-Nissilä L, Jokinen E, Terho P et al. Neurological development of 5-year-old children receiving a low-saturated fat, low-cholesterol diet since infancy: a randomized controlled trial. JAMA 284, 993-1000 (2000).
42. Sánchez-Bayle M, Soriano-Guillén L. Influence of dietary intervention on growth in children with hypercholesterolemia. Acta Paediatr. 92, 1043-1046 (2003).
43. Poustie VJ, Rutherford P. Dietary treatment for familial hypercholesterolaemia. Cochrane Database Syst. Rev. 2, CD001918 (2001).
44. Azadbakht L, Mirmiran P et al. Particle size of LDL is affected by the National Cholesterol Education Program (NCEP) step II diet in dyslipidaemic adolescents. Br. J. Nutr. 98(1), 134-139 (2007).
45. Mietus-Snyder ML, Malloy MJ. Endothelial dysfunction occurs in children with three genetic hyperlipidemias: improvement with antioxidant therapy. J. Pediatr. 133, 35-40 (1998).
46. Raitakari O, Rönnemaa T, Järvisalo MJ et al. Endothelial function in healthy 11-year-old children after dietary intervention with onset in infancy. The Special Turku Coronary Risk Factor Intervention Project for children (STRIP). Circulation 112, 3786-3794 (2005).
47. Hedman M, Matikainen T, Föhr A et al. Efficacy and safety of pravastatin in children and adolescent with heterozygous familial hypercholesterolemia: a prospective clinical follow-up study. J. Clin. Endocrinol. Metab. 90, 1942-1952 (2005).
48. Jones PJ, Raeini-Sarjaz M, Ntanios FY, Vanstone CA, Feng JY, Parsons WE. Modulation of plasma lipid levels and cholesterol kinetics by phytosterol versus phytostanol esters. J. Lipid Res. 41, 697-705 (2000).
49. Weststrate JA, Meijer GW. Plant sterol-enriched margarines and reduction of plasma total and LDL cholesterol concentrations in normocholesterolaemic and mildly hypercholesterolaemic subjects. Eur. J. Clin. Nutr. 52, 334-343 (1998).
50. Gylling H, Siimes MA, Miettinen TA. Sitostanol ester margarine in dietary treatment of children with familial hypercholesterolemia. J. Lipid Res. 36, 1807-1812 (1995).
51. Vuorio AF, Gylling H, Turtola H, Kontula K, Ketonen P, Miettinen TA. Stanol ester margarine alone and with simvastatin lowers serum cholesterol in families with familial hypercholesterolemia caused by the FH-North Karelia mutation. Arterioscler. Thromb. Vasc. Biol. 20, 500-506 (2000).
52. Amundsen AL, Ose L, Nenseter MS, Ntanjos FY. Plant sterol ester-enriched spread lowers plasma total and LDL cholesterol in children with familial hypercholesterolemia. Am. J. Clin. Nutr. 76, 338-344 (2002).
53. Amundsen AL, Ntanios F, Put N, Ose L. Long-term compliance and changes in plasma lipids, plant sterols and carotenoids in children and parents with FH consuming plant sterol ester-enriched spread. Eur. J. Clin. Nutr. 58, 1612-1620 (2004).
54. de Jongh S, Vissers MN, Rol P, Bakker HD, Kastelein JJP, Stroes ESG. Plant sterols lower LDL cholesterol without improving endothelial function in pre-pubertal children with familial hypercholesterolemia. J. Inherit. Metab. Dis. 26, 343-351 (2003).
55. Jakulj L, Vissers MN, Rodenburg J, Wiegman A, Trip MD, Kastelein JJP. Plant stanols do not restore endothelial function in pre-pubertal children with familial hypercholesterolemia despite reduction of low-density lipoprotein cholesterol levels. J. Pediatr. 148, 495-500 (2006).
56. Matsuyama T, Shoji K, Takase H et al. Effects of phytosterols in diacylglycerol as part of diet therapy on hyperlipidemia in children. Asia Pac. J. Clin. Nutr. 16(1), 40-48 (2007).
57. Martino F, Martino E, Morrone F, Carnevali E, Forcone R, Niglio T. Effect of dietary supplementation with glucomannan on plasma total cholesterol and low density lipoprotein cholesterol in hypercholesterolemic children. Nutr. Metab. Cardiovasc. Dis. 15, 174-180 (2005).
58. Haney EM, Huffman LH, Bougatsos C, Freeman M, Steiner RD, Nelson HD. Screening and treatment for lipid disorder in children and adolescents: systematic evidence review for the US Preventive Service Task Force. Pediatrics 120(1), e189-e214 (2007).
59. Daniels SR. Exercise and lipid abnormalities. Pediatr. Cardiol. 20, 71-77 (1999).
60. Raitakari OT, Taimela S, Porkka KVK et al. Associations between physical activity and risk factors for coronary heart disease: The Cardiovascular Risk in Young Finns Study. Med. Sci. Sport Exerc. 29, 1055-1061 (1997).
61. Janz KF, Dawson JD, Mahoney LT. Increases in physical fitness during childhood improve cardiovascular health during adolescence: the Muscatine Study. Int. J. Sports Med. 23, S15-S21 (2002).
62. Katzmarzyk PT, Malina RM, Bouchard C. Physical activity, physical fitness, and coronary heart disease risk factors in youth: the Quebec Family Study. Prev. Med. 29, 555-562 (1999).
63. Kavey REW, Allada VMD, Daniels SR et al. Cardiovascular risk reduction in high-risk pediatric patients. a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research. Circulation 114, 2710-2738 (2006).
64. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1388 (1994).
65. Wiegman A, de Groot E, Hutten BA et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolemia. Lancet 363, 369-370 (2004).
66. Sprecher DL, Daniels SR. Rational approach to pharmacologic reduction of cholesterol levels in children. J. Pediatr. 129, 4-7 (1996).
67. Glueck CJ, Mellies MJ, Dine M, Perry T, Laskarzewski P. Safety and efficacy of long-term diet and diet plus bile acid-binding resin cholesterol-lowering therapy in 73 children heterozygous for familial hypercholesterolemia. Pediatrics 78, 338-348 (1986).
68. Tonstad S, Sivertsen M, Aksnes L, Ose L. Low dose colestipol in adolescents with familial hypercholesterolemia.Arch. Dis. Child 74, 157-160 (1996).
69. Tonstad S, Ose L. Colestipol tablets in adolescents with familial hypercholesterolemia. Acta Paediatr. 85, 1080-1082 (1996).
70. McCrindle BW, O'Neill MB, Cullen-Dean G, Helden E. Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: a randomized, crossover trial. J. Pediatr. 130, 266-273 (1997).
71. Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J. Pediatr. 129, 42-49 (1996).
72. Hussein O, Frydman G, Frim H, Aviram M. Reduced susceptibility of low density lipoprotein to lipid peroxidation after cholestyramine treatment in heterozygous familial hypercholesterolemic children. Pathophysiology 8,21-28 (2001).
73. Asami T, Uchiyama M. Treatment of children with familial hypercholesterolemia with colestilan, a newly developed bile acid-binding resin. Atherosclerosis 164, 381-382 (2002).
74. Armani A, Toth PP. Colesevelam hydrochloride in the management of dyslipidemia. Expert Rev. Cardiovasc. Ther. 4(3), 283-291 (2006).
75. Wierzbicki AS. New lipid-lowering agents. Expert Opin. Emerg. Drugs 8, 365-376 (2003).
76. Arambepola C, Farmer AJ, Perera R, Neil HAW. Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. Atherosclerosis 195, 339-347 (2007).
77. Avis HJ, Vissers MN, Stein EA et al. A systematic review and metaanalysis of statin therapy in children with familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 27, 1803-1810 (2007).
78. Ducobu J, Brasseur D, Chaudron JM et al. Simvastin use in children. Lancet 339, 1488 (1992).
79. Stefanutti C, Lucani G, Vivenzio A, Di Giacomo S. Diet only and diet plus simvastin in the treatment of heterozygous familial hypercholesterolemia in childhood, Drugs Exp. Clin. Res. 25, 23-28 (1999).
80. de Jongh S, Ose L, Szamosi T et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia. A randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 106, 2231-2237 (2002).
81. Dirisamer A, Hachemian N, Bucek RA, Wolf F, Reiter M, Widhalm K. The effect of low-dose simvastatin in children with familial hypercholesterolemia: a 1-year observation. Eur. J. Pediatr. 162, 421-425 (2003).
82. de Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J. Am. Coll. Cardiol. 40, 2117-2121 (2002).
83. Ferreira WP, Bertolami MC, Santos SN et al. One-month therapy with simvastatin restores endothelial function in hypercholesterolemic children and adolescents. Pediatr. Cardiol. 28, 8-13 (2007).
84. Vohl MC, Szots F, Lelievre M et al. Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia. Atherosclerosis 160, 361-368 (2002).
85. Knipscheer HC, Boelen CCA, Kastelein JJP et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr. Res. 39, 867-871 (1996).
86. Wiegman A, Hutten BA, de Groot E et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia. A randomized controlled trial. JAMA 292, 331-337 (2004).
87. Rodenburg J, Vissers MN, Wiegman A et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 116, 664-668 (2007).
88. Koeijvoets KG, Rodenburg J, Hutten BA, Wiegman A, Kastelein JJP, Sijbrands EJG. Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial. Circulation 112, 3168-3173 (2005).
89. Hedman M, Neuvonen PJ, Neuvonen M, Antikainen M. Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia. Clin. Pharmacol. Ther. 74, 178-185 (2003).
90. Hedman M, Antikainen M, Holmberg C et al. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. Br. J. Clin. Pharmacol. 61, 706-715 (2006).
91. Rodenburg J, Vissers MN, Wiegman A et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings. J. Am. Coll. Cardiol. 47, 1803-1810 (2006).
92. Lambert M, Lupien PJ, Gagné C et al. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Pediatrics 97, 619-628 (1996).
93. Stein EA, Illingworth DR, Kwiterovich PO et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. J. Am. Med. Assoc. 281, 137-144 (1999).
94. Kwiterovich PO Jr. Safety and efficacy of treatment of children and adolescents with elevated low density lipoprotein levels with a step two diet or with lovastatin. Nutr. Metab. Cardiovasc. Dis. 11, 30-34 (2001).
95. Clauss SB, Holmes KW, Hopkins P et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics 116, 682-688 (2005).
96. Athyros VG, Papageorglou AA, Kontopoulos AG. Long-term treatment with atorvastatin in adolescent males with heterozygous familial hypercholesterolemia. Atherosclerosis 163, 205-206 (2002).
97. McCrindle BW, Ose L, Marais D. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipemia: a multicenter, randomized, placebo-controlled trial. J. Pediatr. 142, 74-80 (2003).
98. Firth JC, Marais AD et al. Fluvastatin in heterozygous familial hypercholesterolemia. Cardiol. Young 10(Suppl. 2), 35 (2000).
99. van der Graaf A, Nierman MC, Firth JC et al. Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolaemia. Act. Paediatr. 95(11), 1461-1466 (2006).
100. Shepherd J, Vidt DG, Miller E, Harris S, Blasetto J. Safety of rosuvastatin: update on 16876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology 107(4), 433-443 (2007).
101. de Jongh S, Kerckhoffs MC, Grootenhuis MA, Bakker HD, Heymans HS, Last BF. Quality of life, anxiety and concerns among statin-treated children with familial hypercholesterolaemia and their parents. Acta Paediatr. 92, 1096-1101 (2003).
102. Gibbons LW, Gonzalez V, Gordon N, Grundy S. The prevalence of side effects with regular and sustained-release nicotinic acid. Am. J. Med. 99, 378-385 (1995).
103. Tato F, Vega GL, Grundy SM. Effects of crystalline nicotinic acid-induced hepatic dysfunction on serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase. Am. J. Cardiol. 81, 805-807 (1998).
104. Colletti RB, Neufeld EJ, Roff NK, McAuliffe TL, Baker AL, Newburger JW. Niacin treatment of hypercholesterolemia in children. Pediatrics 92, 78-82 (1993).
105. National Cholesterol Education Program. Third report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. NIH publication no. Bethesda, MD, USA, 01-3095 (2001).
106. Steinmetz J, Morin C, Panek E, Siest G, Drouin P. Biological variations in hyperlipidemic children and adolescent treated with fenofibrate. Clin. Chem. Acta 112, 43-53 (1981).
107. Wheeler KAH, West RJ, Lloyd JK, Barley J. Double-blind trial of bezafibrate in familial hypercholesterolemia. Arch. Dis. Child 60, 34-37 (1985).
108. McCrindle, Helden E, Cullen-Dean G, Conner WT. A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. Pediatr. Res. 51, 715-721 (2002).
109. Hedman MD, Miettinen TA, Gylling H et al. Serum noncholesterol sterols in children with heterozygous familial hypercholesterolemia undergoing pravastatin therapy. J. Pediatr. 148, 241-246 (2006).
110. Knopp RH, Gitter H, Truitt T et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur. Heart J. 24, 729-741 (2003).
111. Gagné C, Gaudet D, Bruckert E, for the Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 105, 2469-2475 (2002).
112. Fichtlscherer S, Schmidt-Lucite C, Bojunga S et al. Differential effects of short-term lipid lowering with ezetimibe and statin on endothelial fuction in patients with CAD: clinical evidence for "pleiotropic" functions of statin therapy. Eur. Heart J. 27, 1182-1190 (2006).
113. Raal FJ, Marais AD, Klepack E, Lovalvo J, McLain R, Heinonen T. Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. Atherosclerosis 171, 273-279 (2003).
114. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattingney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: the Bogalusa Heart Study. N Engl. J. Med. 338, 1650-1656 (1998).
115. Mordasini R, Twelsick F, Oster P et al. A comparative study of colestipol and colestyramine in children and adolescents with familial hypercholesterolaemia (author's transl). Monatsschr Kinderheilkd 126, 436-440 (1978).
116. Stein EA. Treatment of familial hypercholesterolemia with drugs in children. Arteriosclerosis 9, 145-151 (1989).
117. Schlierf G, Mrozik K, Heuck CC et al. "Low dose" colestipol in children, adolescents and young adults with familial hypercholesterolemia. Atherosclerosis 41, 133-138 (1982).
118. Groot PHE, Dijkhuis-Stoffelsma R, Grose WFA, Ambagtsheer JJ, Fernandes J. The effects of colestipol hydrochloride on serum lipoprotein lipid and apolipoprotein B and A-I concentrations in children heterozygous for familial hypercholesterolemia. Acta Paediatr. Scand. 72, 81-85 (1983).
119. Glueck CJ, Tsang RC, Fallat RW, Mellies M. Therapy of familial hypercholesterolemia in childhood: diet and cholestyramine resin for 24 to 36 months. Pediatrics 59, 433-441 (1977).
120. West RJ, Lloyd JK, Leonard JV. Long-term follow-up of children with familial hypercholesterolaemia treated with cholestyramine. Lancet 2, 873-875 (1980).
121. Koletzko B, Kupke I, Wendel U. Treatment of hypercholesterolemia in children and adolescents. Acta Paediatr. 81, 682-685 (1992).
122. Liacouras CA, Coates PM, Gallagher PR, Cortner JA. Use of cholestyramine in the treatment of children with familial combined hyperlipidemia.J. Pediatr. 122, 477-482 (1993).
123. Couture P, Brun LD, Szots F et al. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 18, 1007-1012 (1998).
124. Sinzinger H, Schmid P, Pirich C et al. Treatment of hypercholesterolaemia in children. Lancet 340, 548-549 (1992).